Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Politics

FDA declines approval for Amneal Pharmaceuticals’ Parkinson’s drug

by July 4, 2023
July 4, 2023
FDA declines approval for Amneal Pharmaceuticals’ Parkinson’s drug

The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals’ drug for Parkinson’s disease due to inadequate safety data on the treatment to help control symptoms in patients for a longer duration, the company said on Monday.

Shares of Amneal Pharmaceuticals fell 13.1% to $2.7 in choppy after-market trading.

The FDA in a complete response letter said while the company established the safety of one ingredient, levodopa, based on some studies, it was not able to adequately establish safety for the other ingredient, carbidopa.

The health regulator has requested additional information on the safety of the drug, while it did not identify any efficacy or manufacturing issues with the drug.

Amneal’s drug is a new formulation of carbidopa-levodopa, the standard of care for Parkinson’s, and is designed in a way that allows it to remain in a certain area of the small intestine for a longer period, helping in its consistent absorption.

The company said it will work closely with the health regulator to address the issues and plans to meet with the agency.

The health regulator’s decision is a potential hurdle to the company, which has been looking to grow its portfolio of branded drugs, expecting over $500 million in revenues from its specialty business by 2027.

The drugmaker said the decision does not impact its 2023 financial forecast as it did not include the revenue from the drug.

Amneal currently has another Parkinson’s drug, Rytary, which was approved in 2015 in the market but had been struggling to gain a foothold in the treatment space, with only 4% of patients using it.

Parkinson’s is a brain disorder that causes unintended or uncontrollable movements and is the second most-deadly neurodegenerative disease after Alzheimer’s. There is no cure for Parkinson’s currently, but medicines and other therapies can help relieve symptoms.

<!–>

This post appeared first on FOX NEWS
–>

0
FacebookTwitterGoogle +Pinterest
previous post
Williamson torches DNC’s ‘outrageous’ support for Biden in 2024 Dem primary
next post
California city raises minimum wage to $19.08 per hour: highest in America

You may also like

Tucker Carlson Points Out “For Some Reason Twitter...

December 14, 2022

Elections in Brazil: Conservative Jair Bolsonaro Leads the...

October 2, 2022

Democrat Rep. Spanberger allegedly planning run for Virginia...

July 29, 2023

Oscar Winning Singer of “Flashdance” & “Fame” Irene...

November 26, 2022

Hunter Biden attends pre-trial hearing in Delaware court...

May 24, 2024

Trump pledges to release files on JFK, MLK...

January 20, 2025

VP hopefuls dueling for dollars as they show...

May 15, 2024

Biden’s struggle to remember key Cabinet official’s name...

July 3, 2024

Netanyahu and Trump face similar ‘politicized prosecutions,’ legal...

June 3, 2024

The Hitchhiker’s Guide to a probable weekend session...

January 23, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Friday Feature: Incubate Debate

      June 6, 2025
    • Risch urges ‘top to bottom’ USAID spending review after waste, fraud exposed

      June 6, 2025
    • Universities in Libertarian Land

      June 6, 2025
    • Elon Musk may speak to Trump aides in push to calm feud

      June 6, 2025
    • Everyone Talks About Leaving a Better Planet for Our Children: Why Don’t We Leave Better Children for Our Planet?

      June 6, 2025
    • MARK HALPERIN: Democrats try to construct a Frankenstein candidate while JD Vance gains momentum for 2028

      June 6, 2025

    Categories

    • Business (8,149)
    • Investing (2,013)
    • Politics (15,545)
    • Stocks (3,130)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved